Sotrovimab - Covid-19

You are here : Home > Formulary Search > Sotrovimab - Covid-19

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Important

Primary care and outpatient prescribing of antivirals for COVID 19 treatment is through the CMDU service

Documentation

Evidence Review

NICE TA878 CMDU APC briefing paper Jun-23.doc

Webpage

NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Information

Covid Medicines Delivery Unit- update to NICE TA 878 -June 24.pdf

Information

CMDU Community Pharmacies June 2025.pdf

PAD Profile

ChemicalSubstance :

Sotrovimab

Indication :

Covid-19

Group Name :

Keywords :

Covid 19, coronavirus, neutralising monoclonal antibodies, antibody, nMABs, CMDU

Brand Names Include :

Xevudy

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Sotrovimab is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Covid-19.

Committee Recommendations (1)

05 Jul 23 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartland Integrated Care System Area Prescribing Committee agree implementation of NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.

Sotrovimab is agreed as RED for prescription only by the commissioned CMDU service (not for prescribing through A&E / hospital clinics)

*if a patient who falls into one of the high risk cohorts is in hospital and gets COVID-19 (not admitted due to COVID) then these individuals should be treated with Paxlovid / Sotrovimab in line with NICE TA878 whilst they are an inpatient.